Your browser is no longer supported. Please, upgrade your browser.
Settings
EIDX [NASD]
Eidos Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.65 Insider Own1.00% Shs Outstand38.39M Perf Week4.59%
Market Cap4.85B Forward P/E- EPS next Y-3.29 Insider Trans-23.12% Shs Float12.82M Perf Month12.67%
Income-100.80M PEG- EPS next Q-0.81 Inst Own31.00% Short Float3.91% Perf Quarter71.49%
Sales0.10M P/S48478.63 EPS this Y44.60% Inst Trans-3.10% Short Ratio3.15 Perf Half Y160.36%
Book/sh3.20 P/B39.53 EPS next Y-11.90% ROA-53.00% Target Price70.38 Perf Year127.66%
Cash/sh3.84 P/C32.91 EPS next 5Y28.00% ROE-65.20% 52W Range28.39 - 132.54 Perf YTD-3.85%
Dividend- P/FCF- EPS past 5Y- ROI-21.60% 52W High-4.55% Beta-
Dividend %- Quick Ratio11.10 Sales past 5Y- Gross Margin- 52W Low345.61% ATR5.69
Employees70 Current Ratio11.10 Sales Q/Q-99.60% Oper. Margin- RSI (14)61.07 Volatility5.20% 4.55%
OptionableYes Debt/Eq0.14 EPS Q/Q-527.70% Profit Margin- Rel Volume0.56 Prev Close128.51
ShortableYes LT Debt/Eq0.14 Earnings- Payout- Avg Volume159.34K Price126.51
Recom3.20 SMA202.57% SMA5023.80% SMA200101.44% Volume89,215 Change-1.56%
Nov-18-20Downgrade BTIG Research Buy → Neutral
Sep-22-20Downgrade Guggenheim Buy → Neutral
Sep-08-20Initiated Citigroup Buy $80
May-14-20Downgrade JP Morgan Overweight → Neutral $58 → $50
Apr-01-20Resumed BofA/Merrill Neutral $51
Feb-20-20Initiated Guggenheim Buy $66
Feb-18-20Downgrade Barclays Equal Weight → Underweight $45
Nov-01-19Downgrade Barclays Overweight → Equal Weight $37 → $45
Jul-22-19Initiated Piper Jaffray Overweight $55
Feb-27-19Upgrade JP Morgan Neutral → Overweight
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Oct-31-18Initiated ROTH Capital Buy
Jul-16-18Initiated JP Morgan Overweight $36
Jul-16-18Initiated BofA/Merrill Neutral $24
Jul-16-18Initiated Barclays Overweight $32
Jan-13-21 04:30PM  
Jan-12-21 09:30AM  
Jan-08-21 08:30PM  
Jan-06-21 04:54PM  
Jan-05-21 11:26AM  
Jan-04-21 11:42AM  
07:30AM  
Jan-03-21 02:20PM  
Jan-02-21 07:30AM  
Dec-30-20 08:49PM  
10:04AM  
Dec-29-20 11:15AM  
Dec-28-20 08:20PM  
09:15AM  
Dec-26-20 01:55PM  
10:05AM  
Dec-24-20 10:45AM  
09:09AM  
Dec-23-20 09:00PM  
Dec-19-20 04:17PM  
Dec-18-20 10:12PM  
Dec-17-20 11:08PM  
Dec-16-20 01:14PM  
10:10AM  
Dec-14-20 08:42PM  
09:10AM  
Dec-12-20 09:12AM  
Dec-11-20 09:13PM  
08:52PM  
Dec-05-20 05:06AM  
Dec-04-20 08:51PM  
08:00PM  
11:48AM  
Dec-02-20 12:03PM  
Nov-25-20 10:32PM  
08:01AM  
Nov-23-20 08:31PM  
Nov-20-20 09:34PM  
08:30PM  
Nov-19-20 06:36PM  
Nov-13-20 10:35PM  
08:00PM  
07:01PM  
12:30PM  
08:01AM  
Nov-12-20 01:40PM  
Nov-09-20 06:15PM  
Nov-07-20 07:49PM  
Nov-06-20 11:27PM  
08:00PM  
08:01AM  
Nov-05-20 10:53AM  
07:30AM  
Nov-03-20 10:39AM  
Oct-31-20 06:57PM  
Oct-30-20 09:41PM  
03:31PM  
Oct-29-20 04:30PM  
Oct-27-20 10:15AM  
Oct-26-20 06:54PM  
01:37PM  
Oct-24-20 02:10PM  
Oct-23-20 04:44PM  
Oct-22-20 08:37PM  
07:17PM  
05:00PM  
Oct-21-20 10:20PM  
06:48PM  
08:25AM  
Oct-20-20 06:00PM  
03:12PM  
10:00AM  
Oct-19-20 03:24PM  
09:10AM  
Oct-17-20 02:05PM  
Oct-15-20 04:23PM  
12:07PM  
10:45AM  
Oct-14-20 07:00PM  
06:52PM  
03:09PM  
01:14PM  
09:45AM  
Oct-13-20 08:20PM  
12:40PM  
08:03AM  
Oct-12-20 07:40PM  
09:15AM  
08:00AM  
Oct-09-20 06:23PM  
02:38PM  
11:19AM  
09:00AM  
08:01AM  
Oct-08-20 04:00PM  
09:00AM  
Oct-07-20 08:05PM  
06:30PM  
05:36PM  
10:10AM  
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sinha UmaChief Scientific OfficerJan 13Sale124.3210,0001,243,179306,525Jan 15 04:05 PM
Valle FrancoSenior Vice President, FinanceJan 12Option Exercise7.241,74712,6481,747Jan 13 04:05 PM
Valle FrancoSenior Vice President, FinanceJan 12Sale125.451,747219,1520Jan 13 04:05 PM
Valle FrancoSenior Vice President, FinanceJan 11Option Exercise7.241,50010,8601,500Jan 13 04:05 PM
Valle FrancoSenior Vice President, FinanceJan 11Sale125.611,500188,4080Jan 13 04:05 PM
Turtle CameronChief Business OfficerDec 15Option Exercise13.8426,294363,99576,915Dec 16 07:27 PM
Turtle CameronChief Business OfficerDec 15Sale111.7726,2942,938,79650,621Dec 16 07:27 PM
Sinha UmaChief Scientific OfficerDec 02Sale90.045,000450,187316,525Dec 04 05:34 PM
Turtle CameronChief Business OfficerNov 11Sale74.5113,410999,22752,121Nov 13 05:00 PM
Valle FrancoSenior Vice President, FinanceNov 09Option Exercise7.241,62311,7511,623Nov 10 04:05 PM
Valle FrancoSenior Vice President, FinanceNov 09Sale74.931,623121,6090Nov 10 04:05 PM
Turtle CameronChief Business OfficerNov 02Option Exercise14.477,500108,50078,031Nov 03 04:05 PM
Turtle CameronChief Business OfficerNov 02Sale70.7212,500883,95465,531Nov 03 04:05 PM
Sinha UmaChief Scientific OfficerOct 29Sale72.425,000362,099321,525Oct 30 04:55 PM
Valle FrancoSenior Vice President, FinanceOct 08Option Exercise7.245,19937,6415,199Oct 09 05:23 PM
Valle FrancoSenior Vice President, FinanceOct 08Sale74.855,199389,1510Oct 09 05:23 PM
Valle FrancoSenior Vice President, FinanceOct 07Option Exercise7.245,00036,2005,444Oct 09 05:23 PM
Valle FrancoSenior Vice President, FinanceOct 07Sale75.085,444408,7480Oct 09 05:23 PM
Sinha UmaChief Scientific OfficerOct 01Sale52.354,831252,923326,525Oct 02 07:43 PM
Sinha UmaChief Scientific OfficerSep 30Sale52.031698,794331,356Oct 02 07:43 PM
Fox Jonathan CSee RemarksSep 17Sale50.165,767289,259377,673Sep 18 04:06 PM
Fox Jonathan CSee RemarksSep 16Sale50.163,122156,610383,440Sep 16 06:35 PM
Fox Jonathan CSee RemarksSep 15Sale50.061,00050,064386,562Sep 16 06:35 PM
Fox Jonathan CSee RemarksSep 14Sale50.001115,550387,562Sep 16 06:35 PM
Turtle CameronChief Business OfficerSep 10Option Exercise17.002,50042,50073,031Sep 11 04:05 PM
Turtle CameronChief Business OfficerSep 10Sale47.002,500117,50070,531Sep 11 04:05 PM
Turtle CameronChief Business OfficerAug 03Option Exercise13.205,00066,00080,531Aug 05 07:45 PM
Turtle CameronChief Business OfficerAug 03Sale39.9410,000399,45070,531Aug 05 07:45 PM
Fox Jonathan CSee RemarksJul 07Sale50.005,000250,000387,673Jul 09 04:05 PM